- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04712669
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rodatristat Ethyl is a peripherally restricted TPH inhibitor being studied as a potential treatment for PAH. This dose-ranging, randomized, double-blind, placebo-controlled, multicenter study will evaluate the effect of Rodatristat Ethyl from baseline on pulmonary vascular resistance as measured at right heart catheterization.
Patients will be enrolled into a main study with an option to enroll into an open label extension.
The study is expected to enroll patients in the USA, Canada and Europe.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Watiri Kamau-Kelley
- Phone Number: +1-408-300-3316
- Email: watiri@enzyvant.com
Study Contact Backup
- Name: Howard Lazarus, MD, FCCP
- Phone Number: +1-203-297-5374
- Email: howard.lazarus@enzyvant.com
Study Locations
-
-
-
Wien, Austria, 1090
- AKH- Wien, Medizinische Univsersität Wien
-
-
Oberösterreich
-
Linz, Oberösterreich, Austria, 4020
- Ordensklinikum Linz GmbH Elisabethinen
-
-
-
-
Brussels Capital Region
-
Brussels, Brussels Capital Region, Belgium, 1070
- Hôpital Erasme
-
-
Vlaams Brabant
-
Leuven, Vlaams Brabant, Belgium, 3000
- UZ Leuven - Campus Gasthuisberg - Pneumologie
-
-
-
-
-
Banja Luka, Bosnia and Herzegovina, 78 000
- University Clinical Centre of the Republic of Srpska
-
Mostar, Bosnia and Herzegovina, 88000
- University Clinical Hospital Mostar
-
-
-
-
Sofia-Grad
-
Sofia, Sofia-Grad, Bulgaria, 1750
- University MHAT "Sv. Anna"
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T1Y6J4
- Peter Lougheed Centre
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- London Health Sciences Centre - Victoria Hospital
-
Toronto, Ontario, Canada, M5G 2N2
- University Health Network, Toronto General Hospital
-
-
Quebec
-
Montréal, Quebec, Canada, H3T 1E2
- Sir Mortimer B. Davis Jewish General Hospital
-
-
-
-
-
Olomouc, Czechia, 779 00
- Fakultni Nemocnice Olomouc
-
Praha 2, Czechia, 128 08
- Všeobecná fakultní nemocnice v Praze
-
-
-
-
-
Saint-Étienne, France, 42270
- CHU de Saint-Etienne - Hôpital Nord
-
-
Calvados
-
Caen Cedex, Calvados, France, 14033
- Centre Hospitalier Universitaire (CHU) de Caen - Hopital Cote de Nacre
-
-
Rhône
-
Lyon, Rhône, France, 69677
- Groupement Hospitalier Est
-
-
Val-de-Marne
-
Le Kremlin-Bicêtre, Val-de-Marne, France, 94275
- CHU de Bicêtre
-
-
-
-
-
Gießen, Germany, 35392
- Universitätsklinikum Gießen und Marburg
-
-
-
-
-
Genova, Italy, 16132
- AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can
-
Pavia, Italy, 27100
- IRCCS Policlinico San Matteo, Università degli studi di Pavi
-
-
Roma
-
Rome, Roma, Italy, 00161
- Umberto I Policlinico di Roma, Università La Sapienza
-
-
-
-
-
Riga, Latvia, LV-1002
- P.Stradina Clinical University Hospital
-
-
-
-
-
Chisinau, Moldova, Republic of, MD2025
- Spitalul Clinic Republican
-
-
-
-
-
Bialystok, Poland, 15-276
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Lublin, Poland, 20-954
- Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie
-
Otwock, Poland, 05-400
- Europejskie Centrum Zdrowia Otwock Szpital im Fryderyka Chopina
-
-
Lódzkie
-
Łódź, Lódzkie, Poland, 91-347
- Wojewodzki Specjalistyczny Szpital im. dr Wl. Bieganskiego
-
-
-
-
-
Belgrade, Serbia, 11000
- Clinical Center of Serbia
-
-
Vojvodina
-
Sremska Kamenica, Vojvodina, Serbia, 21204
- Institute For Pulmonary Diseases of Vojvodina
-
Sremska Kamenica, Vojvodina, Serbia, 21204
- Institute for Cardiovascular Diseases of Vojvodina
-
-
-
-
-
Barcelona, Spain, 08036
- Hospital Clínic de Barcelona
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
-
-
-
-
Kyiv, Ukraine, 03680
- Nats Naukovyi Tsentr Amn Ukrainy
-
-
Dnipropetrovs'ka Oblast'
-
Dnipropetrovs'k, Dnipropetrovs'ka Oblast', Ukraine, 49070
- Dnipropetrovsk Regional Clinical Diagnostic Center
-
-
-
-
-
London, United Kingdom, NW3 2QG
- Royal Free London NHS Foundation Trust
-
London, United Kingdom, SW3 6NP
- Royal Brompton Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85012
- Arizona Pulmonary Specialists
-
-
California
-
La Jolla, California, United States, 92093
- University of California San Diego Health Sciences
-
Los Angeles, California, United States, 90095
- Ronald Reagan UCLA Medical Center
-
Los Angeles, California, United States, 90073
- VA Greater LA Healthcare System/UCLA
-
Sacramento, California, United States, 95816
- UC Davis Medical Center
-
Santa Barbara, California, United States, 93105
- Jeffrey S. Sager, MD Medical Corporation
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- George Washington University Medical Center
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic Florida
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- The University of Kansas Medical Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Norton Pulmonary Specialists
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital (BWH), Harvard Medical School
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- University of New Mexico Heath Science Center
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Health
-
Rochester, New York, United States, 14623
- University of Rochester
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina Medical Center - Chapel Hill
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati Physicians
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Temple University Hospital
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Brown University - Rhode Island Hospital
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern
-
Houston, Texas, United States, 77030
- Houston Methodist Hospital
-
-
Virginia
-
Falls Church, Virginia, United States, 22042-3307
- Inova Fairfax Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Male and female 18 years or older 2. Body Mass Index (BMI) >18kg/m2 to <=40kg/m2 3. Symptomatic PAH belonging to one of the following 2018 WHO Clinical Group 1 subtypes:
a. Idiopathic PAH b. Heritable PAH c. Drug- or toxin-induced d. PAH associated with:
- Connective tissue disease
- Congenital systemic to pulmonary shunt (atrial septal defect, ventricular septal defect, patent ductus arteriosus) repaired at least one year prior to Screening
Human immunodeficiency virus (HIV) infection - if diagnosed with HIV, must have stable disease status defined as follows:
- stable treatment with HIV medications for at least 8 weeks prior to Screening
- no active opportunistic infection during the Screening Period
- no hospitalizations due to HIV for at least 4 weeks prior to Screening
- WHO FC II or III
Confirmed diagnosis of PAH and meet all the following hemodynamic criteria by means of a screening RHC completed prior to randomization:
- mPAP of >20 mmHg
- PVR ≥ 350 dyne•sec/cm5
- Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) of ≤ 12 mmHg if PVR ≥ 350 and < 500 dyne•sec/cm5, or PCWP/LVEDP ≤ 15 mmHg if PVR ≥ 500 dyne•sec/cm5
- 6MWD of 100 to 550 meters at Screening
- Currently on a stable treatment regimen with one or more treatments approved for PAH. Stable therapy is defined as receiving the same medication(s) for ≥ 12 weeks prior to the screening RHC and at a stable dose level for each for ≥ 8 weeks prior to the screening RHC (see Protocol Section 6.6.2 for approved PAH medications). Any instances where doses of a medication have been missed prior to RHC must be discussed with the Medical Monitor prior to performing the RHC.
Meet all of the following criteria determined by pulmonary function tests completed no more than 24 weeks prior to Screening (performed with or without bronchodilation):
- Forced expiratory volume in one second (FEV1) ≥ 60% of predicted normal, and
- Total lung capacity (TLC) ≥ 70% of predicted normal or FVC ≥ 70% predicted if TLC is not available; For subjects with CTD associated PAH, if TLC is ≥ 60% of predicted but < 70% of predicted of if FVC ≥ 60% or predicted but < 70% of predicted, high resolution computed tomography [HRCT] obtained within 6 months of screening may be utilized to demonstrate limited interstitial lung disease
- If participating in an exercise program for pulmonary rehabilitation, the program must have been initiated ≥ 12 weeks prior to Screening, and patient must agree to maintain the current level of rehabilitation for the first 24 weeks of receiving IP. If not participating in an exercise training program for pulmonary rehabilitation, patient must agree not to enroll in an exercise training program for pulmonary rehabilitation during the Screening Period and the first 24 weeks of receiving IP.
Exclusion Criteria:
- Women of childbearing potential who are pregnant, planning to become pregnant, or lactating or female/male patients unwilling to use effective contraception
- WHO pulmonary hypertension (PH) Group 1 PAH associated with portal hypertension or schistosomiasis; PH due to left heart disease (WHO PH Group 2), lung diseases and/or hypoxia (WHO PH Group 3), chronic thromboembolic PH (WHO PH Group 4), or PH with unclear multifactorial mechanisms (WHO PH Group 5)
- PH associated with significant venous or capillary involvement (PCWP > 15 mmHg), pulmonary capillary hemangiomatosis, portal hypertension, or unrepaired congenital heart defects (CHD)
Three or more of the following risk factors for left ventricular disease:
- BMI > 30 kg/m2
- Diagnosis of essential hypertension that is actively treated
- Diabetes mellitus
- History of significant coronary artery disease (e.g., chronic stable angina, history of coronary intervention within the last 3 months, or a stenosis > 70% at coronary angiography)
- Atrial fibrillation
- Left atrial volume index > 41 mL/m2 [or left atrial diameter (LA) > 4 cm if LAVi unavailable]
- Known genetic hypertrophic cardiomyopathy
- Known cardiac sarcoidosis or amyloidosis
- The patient has a history of, or currently has, a constrictive cardiomyopathy.
- Known history of any left ventricular ejection fraction (LVEF) < 40% by echocardiogram within 3 years of randomization (Note: a transient decline in LVEF below 40% that occurred and recovered more than 6 months before the start of Screening and was associated with an acute intercurrent condition [e.g., atrial fibrillation] is allowed).
Hemodynamically significant valvular heart disease as determined by the Investigator, including:
- greater than mild aortic and/or mitral stenosis and/or
- severe mitral and/or aortic regurgitation (> Grade 3)
- Severe arthritis, musculoskeletal problems, or morbid obesity that, in the opinion of the Investigator, is the cause of the patient's functional limitation and would affect the patient's ability to perform or complete the 6MWT.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rodatristat Ethyl 300 mg BID
Rodatristat ethyl 300 mg tablet BID + standard of care medication(s) taken for 24 weeks
|
rodatristat ethyl 300 mg tablet + matching placebo tablet twice daily on top of standard of care
|
Experimental: Rodatristat Ethyl 600 mg BID
Rodatristat ethyl 600 mg tablet BID + standard of care medication(s) taken for 24 weeks
|
2 rodatristat ethyl 300 mg tablets twice daily on top of standard of care
|
Placebo Comparator: Placebo
Matching placebo tablet + standard of care medication(s) taken for 24 weeks
|
2 matching placebo tablets on top of standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent change from baseline of pulmonary vascular resistance (PVR) as measured by right heart catheterization between active and placebo
Time Frame: From initiation of treatment to Week 24
|
From initiation of treatment to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients who improve in WHO World Health Organization (WHO) Functional Class (FC)
Time Frame: From initiation of treatment to Week 24
|
From initiation of treatment to Week 24
|
Change from baseline in 6MWD
Time Frame: From initiation of treatment to Week 24
|
From initiation of treatment to Week 24
|
Change from baseline in N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) levels
Time Frame: From initiation of treatment to Week 24
|
From initiation of treatment to Week 24
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Howard M Lazarus, MD, FCCP, Altavant Sciences GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RVT-1201-2002 / ELEVATE 2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on rodatristat ethyl 300 mg tablet BID
-
Altavant Sciences GmbHParexel; Altavant Sciences, Inc.Completed
-
Altavant Sciences GmbHCovance; Altavant Sciences, Inc.Completed
-
AstraZenecaCompletedParkinson's DiseaseUnited States
-
Innovation Pharmaceuticals, Inc.CompletedChronic Stable Plaque PsoriasisUnited States
-
Future MedicineRecruitingFM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic SteatohepatitisNonalcoholic Fatty Liver Disease | Nonalcoholic SteatohepatitisSpain, Hungary, Poland
-
RFS Pharma, LLCWithdrawnHuman Immunodeficiency Virus Infection
-
Institute of Hematology & Blood Diseases HospitalNot yet recruitingThe Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, PulmonaryUnited States
-
Biota Pharmaceuticals, Inc.Completed
-
Novartis PharmaceuticalsCompletedHypertensionSweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan